<DOC>
	<DOCNO>NCT00685568</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming . The use celecoxib may keep polyp colorectal cancer form patient familial adenomatous polyposis . PURPOSE : This randomized phase I trial study side effect best dose celecoxib treat young patient genetic predisposition familial adenomatous polyposis .</brief_summary>
	<brief_title>Celecoxib Preventing Colorectal Cancer Young Patients With Genetic Predisposition Familial Adenomatous Polyposis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety toxicity celecoxib pediatric patient genotype-positive familial adenomatous polyposis . Secondary - Determine aberrant crypt focus ( ACF ) adenoma burden entire colorectum patient . - Eliminate learning curve phase II/III trial ( reproducibility endoscopic technique , tolerability procedure ) . - Compare sedation strategy base local standard ( monitored anesthesia care v conscious sedation ) . - Validate ACF score technique . - Establish short-term ( 3 month ) impact celecoxib ACF count order determine appropriateness ACF pathologic endpoint phase II/III trial . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral celecoxib twice daily 3 month absence disease progression unacceptable toxicity . - Arm II : Patients receive oral placebo twice daily 3 month absence disease progression unacceptable toxicity . Patients undergo colonoscopy baseline 3 month . Patients also complete psychosocial questionnaire baseline . Blood sample collect baseline ass influence polymorphism ( CYP2C9 , uridine diphosphate ( UDP ) -glucuronosyl transferase , A6 , glutathione S-transferase [ GST ] M1 , Glutathione S-transferase ( GST ) theta 1 ( GSTT1 ) ) age onset phenotype number colorectal polyp . Plasma drug trough level assess baseline , 1 month , 3 month . After completion study treatment , patient follow periodically 2 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis familial adenomatous polyposis ( FAP ) base genetic predisposition test Genotypepositive FAP ( pathologic Adenomatous polyposis coli ( APC ) mutation ) No attenuated FAP genotype , define follow : Mutation 5 ' end APC exon 4 Exon 9associated phenotype 3 ' region mutation Has intact colon No requirement colectomy Parent ( ) desire colectomy ( regardless adenoma burden ) Colorectal adenoma burden assess baseline colonoscopy No diagnosis severe dysplasia great No 10 adenomas ≥ 1 cm No 100 adenoma size No evidence anemia ( hematocrit &lt; 33 % ) No new diagnosis carcinoma PATIENT CHARACTERISTICS : White Blood Count ( WBC ) &gt; 3,000/μL Platelet count &gt; 100,000/μL Hemoglobin &gt; 10.0 g/dL Aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 1.5 time ULN Total bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history hypersensitivity COX2 inhibitor , sulfonamide , NSAIDs , salicylates No history peptic ulcer disease No significant medical psychiatric problem , opinion principal investigator , would make patient poor candidate study No unacceptable clinical risk ( e.g. , previously unknown bleeding diatheses ) No invasive carcinoma within past 5 year PRIOR CONCURRENT THERAPY : More 3 month since prior investigational agent More 6 month since prior chemotherapy No prior radiotherapy pelvis At least 3 month since prior NSAIDs ( dose ) frequency ≥ 3 times/week At least 1 month since prior NSAIDs ( dose ) frequency &lt; 3 times/week At least 1 month since prior nasal steroid Concurrent Nonsteroidal Antiinflammatory Drugs ( NSAIDs ) allow provide administer ≤ 5 time per month Concurrent orally inhale steroid allow provide administer ≤ 4 week 6month period Concurrent oral intravenous ( IV ) corticosteroid allow provide administer ≤ 2 consecutive week 6month period Concurrent proton pump inhibitor treat gastric reflux allow No concurrent nasal steroids except mometasone ( Nasonex ) No concurrent fluconazole , lithium , adrenocorticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>familial adenomatous polyposis</keyword>
</DOC>